Search research articles
Contact Us
Filters
Showing results (451-460 of 511) with videos related to
Page
of 52
Sort By:
Iscience
|
June 29, 2026
Pan-cancer analysis reveals Rho kinase addiction as a vulnerability of de-differentiated cancer cells
Jaume Barcelo, Yumiko Teigen, Joshua Alexander James Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2012
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
C K Lee, R J Simes, C Brown, et al.
Cell Reports
|
March 8, 2016
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
James Campbell, Colm J Ryan, Rachel Brough, et al.
Nature Communications
|
July 8, 2025
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models
Joan Kyula-Currie, Victoria Roulstone, James Wright, et al.
Cell Reports
|
May 10, 2023
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells
Anabel Zelceski, Paola Francica, Lea Lingg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 23, 2020
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
Timothy A Yap, Brent O'Carrigan, Marina S Penney, et al.
Molecular Cell
|
December 17, 2020
Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
Graeme Hewitt, Valerie Borel, Sandra Segura-Bayona, et al.
The Journal of Clinical Investigation
|
February 16, 2018
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade
Mehdi Touat, Tony Sourisseau, Nicolas Dorvault, et al.
Cancer Discovery
|
May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Suzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
Cancer Research
|
August 30, 2014
Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling
Shan Gao, Ilirjana Bajrami, Clare Verrill, et al.
Page
of 52
Search research articles
Search
Showing results (451-460 of 511) with videos related to
Sort By:
Page
of 52
Iscience
|
June 29, 2026
Pan-cancer analysis reveals Rho kinase addiction as a vulnerability of de-differentiated cancer cells
Jaume Barcelo, Yumiko Teigen, Joshua Alexander James Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2012
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
C K Lee, R J Simes, C Brown, et al.
Cell Reports
|
March 8, 2016
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
James Campbell, Colm J Ryan, Rachel Brough, et al.
Nature Communications
|
July 8, 2025
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models
Joan Kyula-Currie, Victoria Roulstone, James Wright, et al.
Cell Reports
|
May 10, 2023
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells
Anabel Zelceski, Paola Francica, Lea Lingg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 23, 2020
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
Timothy A Yap, Brent O'Carrigan, Marina S Penney, et al.
Molecular Cell
|
December 17, 2020
Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
Graeme Hewitt, Valerie Borel, Sandra Segura-Bayona, et al.
The Journal of Clinical Investigation
|
February 16, 2018
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade
Mehdi Touat, Tony Sourisseau, Nicolas Dorvault, et al.
Cancer Discovery
|
May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Suzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
Cancer Research
|
August 30, 2014
Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling
Shan Gao, Ilirjana Bajrami, Clare Verrill, et al.
Page
of 52